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Summary
 
Coupling of an antibody response to effector cells through the Fc region of antibodies is a fun-
damental objective of effective vaccination. We have explored the role of the Fc receptor sys-
tem in a murine model of 
 
Cryptococcus neoformans
 
 protection by infecting mice deleted for the
common 
 
g
 
 chain of FcRs. Passive administration of an IgG1 mAb protects FcR
 
g
 
1
 
/
 
2
 
 mice in-
fected with 
 
C. neoformans
 
, but fails to protect FcR
 
g
 
2
 
/
 
2
 
 mice, indicating that the 
 
g
 
 chain acting
through Fc
 
g
 
RI and/or III is essential for IgG1-mediated protection. In contrast, passive ad-
ministration of an IgG3 mAb with identical specificity resulted in enhanced pathogenicity in 
 
g
 
chain–deficient and wild-type mice. In vitro studies with isolated macrophages demonstrate
that IgG1-, IgG2a-, and IgG2b-opsonized 
 
C. neoformans
 
 are not phagocytosed or arrested in
their growth in the absence of the FcR
 
g
 
 chain. In contrast, opsonization of 
 
C. neoformans
 
 by
IgG3 does not require the presence of the 
 
g
 
 chain or of FcRII, and the internalization of IgG3-
treated organisms does not arrest fungal growth.
 
C
 
ryptococcus neoformans
 
 is an encapsulated fungus that in-
fects immunosuppressed individuals and is responsible
for the death of 6–8% of AIDS patients (1). Antibodies to
the glucuronoxylomannan (GXM)
 
1
 
 portion of the capsular
polysaccharide modulate the infection (2). We have previ-
ously demonstrated that anticryptococcal IgG3 mAbs are
not protective in mouse models of cryptococcal infection
(3–5). However, when the nonprotective IgG3 mAbs were
switched in vitro to other downstream IgG isotypes, these
antibodies became protective (4, 5). Since the IgG3 anti-
bodies and their switch variants have identical antigen
binding sites (5), this observation underscores the impor-
tance of Fc-mediated functions for antibody efficacy against
 
C. neoformans.
 
 In principle, the Fc domain of IgG immune
complexes can interact with a variety of soluble and cell-
bound molecules that may be involved in mediating the
protective capacity of this antibody. Thus, complement
C1q binding can lead to the activation of C3, which leads
in turn to either association with CR1/2 or generation of a
membrane attack complex through C5 (6). Direct interac-
tion of IgG1 complexes with cognate FcRs could mediate
either fungal killing, or the arrest of fungal growth through
NK or macrophage-mediated antibody-dependent cytotox-
icity (ADCC) (7), macrophage phagocytosis, or neutrophil
activation (8). Finally, IgG1, through its interaction with
the FcRn transporter (for review see reference 9), could be
involved in clearance of opsonized cells.
In this study, we have begun the dissection of the mech-
anisms by which IgG subclasses mediate their biological
responses by comparing the capacity of the IgG3 and the
IgG1 isotypes to (
 
a
 
) modulate cryptococcal infection in FcR-
deficient mice in vivo and (
 
b
 
) mediate macrophage phago-
cytosis and the arrest of fungal growth in vitro. Three differ-
ent classes of murine Fc receptors for IgG (Fc
 
g
 
RI, Fc
 
g
 
RII
and Fc
 
g
 
RIII) have been identified on immune effector
cells (for review see references 10–12). Activation by cross-
linking of Fc
 
g
 
RI and III on macrophages, NK cells, mast
cells, neutrophils, and other myeloid cells by antigen–anti-
body complexes leads to activation of diverse biological re-
sponses including phagocytosis, ADCC (for review see ref-
erences 10, 12, 13), and release of inflammatory mediators
(for review see reference 14). The 
 
g
 
 subunit of Fc receptors
is an essential component of type I and III receptors for IgG
antibodies and is required for both receptor assembly and
signal transduction (15, 16). FcR
 
g
 
 chain deletion leads to
impaired macrophage phagocytosis of IgG-coated SRBCs
despite persistent binding, and leads to defects in NK cell–
 
1
 
Abbreviations used in this paper:
 
 ADCC, antibody-dependent cytotoxicity;
GXM, glucuronoxylomannan.
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mediated ADCC (17). In contrast, cross-linking of Fc
 
g
 
RII
does not elicit a biological response on effector immune
cells. However, when coligated to an activation receptor,
such as Fc
 
g
 
RIII, B cell receptor, or TCR, Fc
 
g
 
RII inhibits
the activation signal generated in those cells by inhibiting
calcium influx to the cell through the recruitment of the
SH2 inositol polyphosphate phosphatase SHIP (18, 19).
Deletion of Fc
 
g
 
RII results in mice with hyperresponsive B
cells, mast cells, and macrophages (20).
Here, we report that the FcR
 
g
 
 chain–deficient mice and
heterozygous littermate controls are equally susceptible to
cryptococcal infection and that 
 
g
 
 chain is essential for
IgG1-mediated passive protection against this pathogen. In
addition, IgG3 mediated the phagocytosis of 
 
C. neoformans
 
and SRBCs in the absence of Fc
 
g
 
RI, II, or III function,
suggesting that it either uses a different FcR for IgG3 or a
signal transduction pathway that is different from the other
Fc
 
g
 
Rs. In contrast to the ability of IgG1 and IgG2a mAbs
to inhibit fungal growth, IgG3-mediated phagocytosis is
not associated with the arrest of fungal replication. The
findings in this study provide a rationale for the different
protective efficacies of IgG3 and IgG1 mAbs in mice in-
fected with 
 
C. neoformans.
 
Materials and Methods
 
C. neoformans.
 
Strain 24067 (serotype D) was obtained from
the American Type Culture Collection (Rockville, MD) and
maintained on Sabouraud dextrose agar (Difco, Detroit, MI) at
4
 
8
 
C. For murine infection, 
 
C. neoformans
 
 was grown at 37
 
8
 
C in
Sabouraud dextrose broth (Difco) for 24 h. Yeast cells were
washed three times with PBS and the inoculum was determined
by counting in a hemocytometer and by scoring the CFU plated
on Sabouraud dextrose agar plates.
 
Monoclonal Antibodies.
 
The 3E5 IgG3 was made in response
to immunization with the GXM fraction of the 
 
C. neoformans
 
capsular polysaccharide conjugated to tetanus toxoid (21). The
IgG1, IgG2a, and IgG2b switch variants of 3E5 IgG3 were gener-
ated by in vitro isotype switching (5). The variable region se-
quence of the IgG1 switch variant was sequenced and is identical
to 3E5 IgG3 and all of the switch variants bind GXM (5). Ascites
was obtained by injecting 10
 
7
 
 hybridoma cells into the peritoneal
cavity of Pristane-primed (Sigma Chemical Co., St. Louis, MO)
BALB/c mice. Antibody concentration was determined by an
ELISA relative to isotype matched standards of known concentra-
tion. For in vitro studies, antibodies were purified by protein G
chromatography (Pierce Chemical Co., Rockford, IL), and were
sterilized by filtering through a 0.2-mm-pore-size membrane
(Sigma Chemical Co.). For some in vitro experiments, the puri-
fied antibodies were incubated at 56
 
8
 
C for 30 min to inactivate
complement. Purified anti-SRBC mAbs (anti-SRBC IgG1,
IgG2a, IgG2b, and IgG3) for rosetting assays were supplied by Dr.
B. Diamond (Albert Einstein College of Medicine; reference 22).
 
Animal Experiments.
 
Female C57BL/6J mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). FcR
 
g
 
 chain
knockout (FcR
 
g
 
2
 
/
 
2
 
) mice and wild-type (FcR
 
g
 
1
 
/
 
1
 
) or het-
erozygous (FcR
 
g
 
1
 
/
 
2
 
) controls had been backcrossed to C57BL/
6J for eight generations. Mice kept under specific pathogen-free
conditions were used for protection experiments at 6 wk of age.
10 mice per group were given 1 mg of IgG1, IgG3, or PBS as a
control. mAbs were administered via intraperitoneal injection 24 h
before intravenous challenge with 5 
 
3
 
 10
 
6
 
 
 
C. neoformans
 
, and
mouse deaths were recorded daily.
 
Organ CFUs and Serum GXM Levels.
 
Groups of five mice
were treated with 1 mg of IgG1, IgG3, or PBS 1 d before infec-
tion. CFUs were determined 14 d after infection by plating ho-
mogenized brain or lung tissue on Sabouraud dextrose agar (5).
CFUs are expressed as the mean 
 
6
 
 SD.
Serum GXM levels were determined by capture ELISA. Be-
fore ELISA, serum obtained 14 d after infection was diluted 1:25
with PBS, incubated overnight at 37
 
8
 
C with 0.2 mg/ml of pro-
teinase K, and then heated for 20 min at 100
 
8
 
C (5). Serum GXM
concentration was determined relative to GXM standards of
known concentration.
 
In Vitro Macrophage Phagocytosis.
 
Bronchoalveolar macrophage
cells were obtained from C57BL/6J, FcR
 
g
 
1
 
/
 
1
 
, FcR
 
g
 
2
 
/
 
2
 
, or
FcR
 
g
 
-chain and Fc
 
g
 
RII double knockout (FcR
 
g
 
2
 
/
 
2
 
 /RIIB
 
2
 
/
 
2
 
)
mice (Clynes, R., unpublished observations). For the phagocyto-
sis assay, 10
 
5
 
 cells were plated per well in 96-well tissue culture
plates (Falcon; Becton Dickinson, Mountain View, CA) and cul-
tured overnight at 37
 
8
 
C in the presence of 500 U of IFN-
 
g
 
 per
ml (Genzyme, Cambridge, MA). Phagocytosis was measured in
the presence or absence of purified mAbs.
Phagocytosis of 
 
C. neoformans
 
 by macrophages without IFN-
 
g
 
pretreatment was studied in the same manner. After the addition
of 
 
C. neoformans
 
 (E/T ratio of 1:5), the cells were incubated at
37
 
8
 
C for 4 h, washed three times with sterile PBS to remove
nonadherent yeast cells, fixed with cold absolute methanol, and
stained with a 1:20 solution of Giemsa stain (Sigma Chemical
Co.). Phagocytic indices were determined with a microscope at a
magnification of 
 
3
 
600 (Nikon Diaphot; Nikon Inc., Melville,
NY). The phagocytic index is the number of macrophages with
two or more internalized yeast cells/total number of macrophages
in each field. For each experiment, eight fields were counted (23).
 
In Vitro Macrophage Antifungal Activity.
 
The antifungal effi-
cacy of primary macrophage cells was determined by counting
the 
 
C. neoformans
 
 CFU after coculturing with macrophage cells
(E/T 
 
5
 
 5:1) in the presence and absence of mAb as previously
described (24). In brief, the macrophage cells were mixed with 
 
C.
neoformans
 
 in the presence of 5 
 
m
 
g of mAb per milliliter as de-
scribed for the phagocytosis assay, and the mixture was incubated
for 2 or 24 h. The supernatants from each well were then re-
moved and the cells were lysed with sterile water for 30 min at
37
 
8
 
C, then vigorously aspirated and ejected in order to com-
pletely disrupt them. The supernatant was added back to the ly-
sate, diluted with PBS, and plated on Sabouraud dextrose agar
plates. Results are expressed as mean 
 
6
 
 SD.
 
Rosetting Assay.
 
SRBCs were purchased from Colorado Se-
rum Company (Denver, CO). The preparation of Ig-coated
SRBC and Fc rosetting was done as previously described (25, 26).
In brief, 1–5 
 
m
 
g of mAb was incubated with 1 ml of SRBCs (2 
 
3
 
10
 
7
 
 cells) for 30 min at 37
 
8
 
C, washed, and then diluted 1:10. The
Ig-coated SRBCs were added to the adherent cells in 96-well
plates (E/T 
 
5
 
 1:20), incubated for 30 min at 37
 
8
 
C, and then
washed and assayed for rosettes. Attachment of three or more
SRBCs signified a rosette. For phagocytosis, the cells were incu-
bated for 1 or 2 h at 37
 
8
 
C, then free SRBCs were lysed with dis-
tilled water and intracellular SRBCs were assayed using phase
contrast microscopy. SRBCs incubated in the absence of mAbs
were used as controls. Results are expressed as the mean 
 
6
 
 SD.
 
Statistics.
 
Data were analyzed with statistical software for
Macintosh (Instat version 2.01; GraphPDA Software for Science,
San Diego, CA) using the unpaired Student 
 
t
 
 test. Results were 
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also analyzed by the unpaired Wilcoxon test, which gave similar
results (4, 27).
 
Results
 
Effects of mAbs on Survival of FcR
 
g
 
1
 
/
 
2
 
 Mice. We have
previously demonstrated that 3E5 IgG3 mAb was not pro-
tective against lethal infection of immunocompetent
C57BL/6J mice with C. neoformans, whereas its IgG1
switch variant prolonged the life of the infected animals
(27). C57BL/6J and the FcRg1/1 and FcRg1/2 litter
mates of FcRg2/2 homozygous mice were infected with a
lethal dose of C. neoformans to quantify their susceptibility
to infection. All four mouse strains had similar susceptibility
to cryptococcal infection (P 5 0.8; Table 1). To determine
the effect of the IgG3 and IgG1 isotypes on FcRg1/2 mice,
we treated groups of 10 mice with IgG3, IgG1, or PBS and
then challenged them with C. neoformans. Consistent with
previous results (27), IgG3 mAb tended to reduce animal
survival when compared to PBS controls (Fig. 1), although
the difference in survival time was not statistically signifi-
cant (P 5 0.14; Table 1). FcRg1/2 mice given IgG1 mAb
were significantly protected compared to PBS controls (P
,0.02; Table 1 and Fig. 1). Animal survival in 3E5 IgG3–
and IgG1-treated C57BL/6J and FcRg1/1 mice was compa-
rable to that in FcRg1/2 mice (data not shown). Thus, the
in vivo data confirm that the isotype of the mAb is an im-
portant determinant of protection against C. neoformans and
that the heterozygous FcRg1/2 mice do not differ in their
susceptibility to infection or response to passive antibody
from wild-type mice.
Effects of mAbs on Survival of FcRg2/2 Mice. To deter-
mine whether FcgRs play a role in antibody-mediated im-
munity against cryptococcal infection, FcRg2/2 mice were
challenged with C. neoformans as described above. Interest-
ingly, FcRg2/2 mice had similar susceptibility to crypto-
coccal infection compared to FcRg1/2 mice indicating that
lack of the FcRg chain does not reduce natural resistance
to cryptococcal infection (P .0.9; Fig. 2, inset). Passive ad-
ministration of IgG1 mAb failed to protect FcRg2/2 mice
against infection, and it even appeared to lessen animal sur-
vival at early intervals after infection compared to PBS con-
trols, but there was not a statistically significant shortening
of animal survival overall (Fig. 2 and Table 1). However,
IgG3 mAb did significantly reduce animal survival (P
,0.004). These results indicate that the FcRg chain is cru-
cial for IgG1-mediated protection against cryptococcal in-
fection, and suggest that the accelerated infectious process
provoked by IgG3 is mediated through a different pathway.
Effects of mAbs on Organ CFUs and Serum GXM Levels of
FcRg2/2 Mice. The animal survival data for FcRg2/2
mice were extended by quantifying organ C. neoformans
CFUs and serum GXM antigen levels. Table 2 shows that
14 d after infection lung and brain CFU number and serum
GXM antigen in IgG1-treated FcRg2/2 mice were similar
to PBS-treated controls. In contrast, mice treated with IgG3
had many more organisms in their lungs compared to con-
trols or IgG1-treated mice (P ,0.02), but no increase in
brain CFUs was found. The level of circulating GXM anti-
gen in IgG3-treated mice was also elevated, suggesting a
higher fungal burden (P ,0.03, Table 2). These results are
consistent with the animal survival studies and indicate that
the FcRg chain is necessary for IgG1-mediated protection.
Effects of mAbs on Macrophage Phagocytosis In Vitro. Phago-
cytosis by macrophages derived from wild-type, FcRg2/2
and FcRg2/2/RIIB2/2 mouse strains was studied to fur-
ther define the roles of FcRs in this model. In the absence
of capsule-specific mAbs, there was little or no phagocyto-
sis of C. neoformans by lung macrophages (Fig. 3 A). Addi-
tion of IgG1, IgG2b, or IgG2a mAbs to the normal mac-
rophage assay significantly increased the phagocytic index,
especially after IFN-g stimulation (P ,0.0001), whereas
Table 1. Survival in Days of FcRg1/2 and FcRg2/2 Mice 
Challenged with C. neoformans
FcRg1/2 P , FcRg2/2 P ,
mAbs (3E5)
IgG1 270 6 130 0.02‡ 112 6 29 0.21‡
IgG3 102 6 56 0.14§ 64 6 22 0.004§
PBS control 147 6 74 0.02* 159 6 18 0.20*
Controls
PBS FcRg1/1 156 6 22
PBS (C57BL/6) 159 6 22 0.8i
*PBS versus IgG1.
‡IgG1 versus IgG3.
§IgG3 versus PBS.
iPBS (FcRg1/2) versus other PBS controls (C57BL/6J, FcRg1/1,
FcRg2/2) (unpaired Student’s t test).
Figure 1. Survival of FcRg1/2 mice given either mAbs IgG1, IgG3, or
PBS. 1.0 mg of each antibody was given intraperitoneally 24 h before in-
travenous challenge with 5 3 106 C. neoformans. Average survival and
standard deviation for the IgG1, IgG3, and PBS groups were 270 6 130,
101 6 56, and 147 6 74 d, respectively.644 Isotypes and FcRs in Cryptococcal Infection
the IgG3 mAb induced less phagocytosis (9%; P ,0.0001).
Addition of IFN-g significantly increased IgG3-mediated
phagocytosis (19%) indicating that IFN-g caused an in-
crease in expression of the FcgR responsible IgG3-medi-
ated phagocytosis. When IgG1, IgG2a, or IgG2b mAbs were
added to FcRg2/2 macrophages, little or no phagocytosis
was observed even after stimulation with IFN-g (Fig. 3 B),
and analysis of macrophages from either the bone marrow
or the peritoneal cavity gave similar results (data not
shown). Organisms treated with IgG3 were poorly phagocy-
tosed by FcRg2/2 macrophages without IFN-g stimulation.
However, IFN-g pretreatment of FcRg2/2 macrophages dra-
matically increased IgG3-mediated phagocytosis (P ,0.0001).
IgG3 mAb pretreated by heating at 568C to inactivate
complement still provoked similar phagocytosis by the
macrophages from FcRg2/2 or FcRg2/2/RIIB2/2 mice
(data not shown). To exclude the possibility that the phago-
cytosis was mediated through FcgRIIB, we assayed macro-
phages from FcgRIIB2/2 (20) and FcRg2/2/RIIB2/2 mice
and similar results were obtained (data not shown).
To confirm the data obtained from the macrophage assay
with anticryptococcal mAbs, we also examined mAb-medi-
ated rosetting of SRBCs. Fig. 4 A shows that there is little
rosetting in the absence of mAbs in FcRg1/1 mouse mac-
rophage cells. The anti-SRBC IgG1, IgG2a, and IgG2b in-
duced high levels of rosetting, which was consistent with ear-
Figure 2. Survival of FcRg2/2
mice infected with C. neoformans
after the administration of mAbs.
Average survival and standard
deviation of FcRg2/2 mice for
the IgG1-, IgG3-, and PBS-
treated groups were 112 6 95,
64.0 6 70, and 158 6 57 d, re-
spectively. The 3E5 IgG1 mAb
failed to protect FcRg2/2 mice
(P 5 0.20), whereas the IgG3
mAb decreased survival (P
,0.004). (inset) FcRg2/2 mice
were similarly susceptible to
cryptococcal infection as FcRg1/2
mice (P ,0.8).
Table 2. Organ CFUs and Serum GXM Levels 14 d after Infection
Lung CFUs
(3 104) P <
Brain CFUs
(3 104) P < GXM P <
mg/ml
FcRg2/2
IgG1 47 6 27 0.01‡ 71 6 33 0.72‡ 0.68 6 0.27 0.13‡
IgG3 196 6 80 0.02§ 81 6 49 0.61§ 1.95 6 0.95 0.03§
PBS 56 6 43 0.74* 66 6 32 0.82* 0.51 6 0.18 0.29*
FcRg1/2
PBS 64 6 21 0.82i 78 6 51 0.67i 0.47 6 0.12 0.70i
*PBS versus IgG1.
‡IgG1 versus IgG3.
§IgG3 versus PBS.
iPBS (FcRg1/2) versus PBS (FcRg2/2) (unpaired Student’s t test).645 Yuan et al.
lier reports (26). As with C. neoformans, IgG3 induced
lower rosetting levels compared to other IgG isotypes (P
,0.001). When the same mAbs were added to macro-
phages from the FcRg2/2 mice, IgG1 and IgG2b mAbs in-
duced lower frequencies of rosetting, and only 30% of the
cells rosetted with IgG2a (Fig. 4 B). Again, IgG3-treated
SRBCs had a relatively low frequency of rosetting (13–
17%) with both macrophages from the FcRg2/2 and the
FcRg2/2/RIIB2/2 double knockout mice (Fig. 4, B and
C). Very limited rosetting was observed in IgG1-, IgG2a-, or
IgG2b-treated FcRg2/2/RIIB2/2 macrophages (Fig. 4 C).
Prolonged incubation (2 h) with IgG1-, IgG2b- or IgG2a-
treated SRBCs did not result in phagocytosis (data not
shown). Consistent with the results from the macrophage
phagocytosis assay using C. neoformans, IgG3-treated SRBCs
had a 10–12% phagocytic index with the FcRg2/2/RIIB2/2
macrophages (data not shown). Taken together, these ob-
servations suggest that an IgG3 Fc receptor expressed on
the cell surface of mouse primary macrophages differs from
the other FcgRs or IgG3-mediated phagocytosis is depen-
dent upon a different pathway of activation than the other
FcRs.
Effects of mAbs on Macrophage on the Growth of C. neofor-
mans In Vitro. We next determined whether binding this
FcgR-IgG3 would lead to fungal killing after phagocytosis.
Antifungal activity was quantified by measuring the CFU
after incubating antibody, C. neoformans, and macrophages
pretreated with IFN-g. Table 3 (FcRg1/1) shows that
IgG1 mAb significantly reduced the CFUs when incubated
with wild-type alveolar macrophages at both early (2 h)
and later (24 h) coculture periods. In contrast, IgG3 mAb
did not restrain the growth of the organism after 2 or 24 h
of coculture. Macrophages obtained from FcRg2/2 mice
(FcRg2/2) had little or no effect on CFU number in the
presence of IgG1 mAb (P ,0.6). The CFUs of the IgG3-
treated organisms increased the same as the controls (P .0.6)
when they were cocultured with FcRg2/2 macrophages.
These results strongly suggest that the FcgRs for IgG1 me-
diate phagocytosis and the release of factors leading to the ar-
rest of fungal growth. In contrast, IgG3 induced phagocy-
tosis of the organism but failed to inhibit fungal replication.
Discussion
The interaction of antibody–antigen complexes with ef-
fector cells results in a variety of different immune re-
sponses that are initiated through the binding of the anti-
body Fc region to cell surface Fc receptors. As a result, both
the structural heterogeneity of FcRs on effector cells and
the different antibody isotypes may contribute to the diver-
sity of the response of effector cells (28, 29). Passive 3E5
IgG1 administration significantly prolongs survival of nor-
mal FcRg1/1 and FcRg1/2 mice challenged with a lethal
dose of C. neoformans, whereas IgG3 with the identical var-
iable region does not protect and even shows a tendency to
reduce animal survival. The different protective efficacy
mediated by this pair of IgG1 and IgG3 mAbs confirms our
previous findings (5, 27) and strongly suggests that Fc-medi-
ated effector functions play an important role in protection
against C. neoformans.
The role of the FcgRs in natural resistance against cryp-
tococcal infection or any microbial pathogen is unknown.
Figure 3. Effects of 3E5 mAbs on phago-
cytosis by bronchoalveolar macrophage cells
from FcRg1/1 and FcRg2/2 mice. Phago-
cytic index was determined at an E/T ratio
of 1:1 after 4 h of incubation. Each bar rep-
resents the average of eight fields, and
brackets denote standard deviation.
Table 3. Effects of mAbs on C. neoformans CFU after Coculture 
with Bronchoalveolar Macrophages for 2 and 24 h
2 h
(3 103) P <
24 h
(3 103) P <
FcRg2/2
IgG1 18 6 4 0.58‡ 281 6 39 0.44‡
IgG3 20 6 5 0.45§ 309 6 79 0.67§
Control 19 6 4 0.75* 293 6 30 0.53*
FcRg1/1
IgG1 7 6 2 0.001‡ 159 6 27 0.0002‡
IgG3 15 6 4 0.76§ 263 6 35 0.79§
Control 14 6 4 0.008* 269 6 32 0.0001*
*PBS versus IgG1.
‡IgG1 versus IgG3.
§IgG3 versus PBS (unpaired Student’s t test).646 Isotypes and FcRs in Cryptococcal Infection
Our finding that FcRg chain–deficient mice, which are un-
able to phagocytose through FcgRI and III, have similar sus-
ceptibility to C. neoformans to normal C57BL/6J or FcRg1/2
mice, suggests that FcgRI and III are not essential for natural
resistance against cryptococcal infection. Most wild-type
mice infected with C. neoformans do not develop an anti-
body response and antibody-mediated clearance is not be-
lieved to play a significant role in natural resistance (30).
Even in those animals that do produce antibodies, there is a
mixture of protective and nonprotective antibodies, and
the latter may block the effects of the former (4). It is likely
that FcRg chain–deficient mice have a similar response,
and therefore the presence or absence of FcgRs has no sig-
nificant consequence for natural resistance.
The observation that passively administered 3E5 IgG1
fails to protect FcRg2/2 mice against cryptococcal infec-
tion clearly demonstrates that the FcRg chain is essential
for IgG1-mediated protection. An analogous situation has
been observed in a passive protection model to metastatic
melanoma. Administration of an IgG2b mAb to the me-
lanosome protein gp75 is able to protect wild-type mice
from significant lung metastasis. This protective effect is
abolished in FcRg chain–deficient mice, demonstrating the
essential role of FcgR-mediated ADCC in the mechanism
of antibody protection (30a). Deletion of FcRg chain leads
to defects of macrophage phagocytosis, ADCC, and other
cytotoxic activities (13, 17), offering a likely explanation
for the lack of protection by passive administration of
IgG1, IgG2a, or IgG2b mAbs. The loss of the g chain in
vivo has also been shown to result in a decreased ability to
clear RBCs opsonized with rabbit IgG anti–mouse RBCs,
induce thrombocytopenia with an IgG1 mAb, or mount an
Arthus reaction to IgG1, IgG2a, or IgG2b immune com-
plexes (17, 31). IgG3 immune complexes, in contrast, re-
tained the ability to induce the cutaneous inflammatory re-
sponse of an Arthus reaction (31). Those results are consistent
with the data presented here in which macrophages derived
from FcRg chain–deficient mice are unable to phagocytose
IgG1-, IgG2b-, and IgG2a-treated particles, but retain the
ability to bind and phagocytose IgG3-treated particles in
vitro and enhance infection in FcRg2/2 mice in vivo. Our
studies show that interaction of the IgG1–C. neoformans
complex with Fc receptors on normal macrophages signifi-
cantly inhibits replication of C. neoformans. However, the
in vitro fungal inhibitory activity of IgG1 mAb is abolished
completely when FcRg chain–deficient macrophages are
tested. Consistent with the in vivo study, IgG3 treatment
permitted the organisms to replicate when tested with both
normal and FcRg2/2 macrophages.
Our data extends the earlier finding by Diamond et al.
(26) and suggests that there is either a separate receptor for
IgG3 or a different pathway to activate phagocytosis on pri-
mary mouse macrophages and macrophage-like cell lines.
IFN-g stimulates expression of FcgRs (32), which was con-
firmed in our in vitro studies using normal mouse macro-
phages. More importantly, treatment with IFN-g and IgG1
mAb had a synergistic effect on promoting phagocytosis
and inhibiting proliferation of C. neoformans within normal
macrophages, which is abolished in FcRg deficient mac-
rophages. In contrast, exposure to IFN-g significantly pro-
motes IgG3 FcR expression in both normal and FcRg2/2
macrophages. The interaction of this receptor with IgG3
Figure 4. Rosetting of anti-SRBC IgGs by macrophages from FcRg1/1
(A), FcRg2/2 (B), and FcRg2/2/RIIB2/2 (C) mice. Anti-SRBC mAbs
(5 mg/ml) were incubated with SRBCs (2 3 107 cells) for 30 min before
adding to the adherent macrophages (E/T 5 1:20). Attachment of three
or more SRBCs signified a rosette. SRBCs incubated in the absence of
mAbs were used as controls. Results are expressed as the mean 6 SD.647 Yuan et al.
mAb failed to inhibit C. neoformans replication. We previ-
ously demonstrated that IFN-g plays an important role in
stimulating both IgG1-mediated protection and IgG3-
mediated enhancement of infection (27). It is possible that
IgG3-mediated phagocytosis actually provides an intracel-
lular sanctuary for C. neoformans that allows the fungus to
escape killing by other effector cells and serum factors.
Fungi could then proliferate freely within macrophage cells
and be disseminated, finally killing the host.
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